JP2018509175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509175A5 JP2018509175A5 JP2017551580A JP2017551580A JP2018509175A5 JP 2018509175 A5 JP2018509175 A5 JP 2018509175A5 JP 2017551580 A JP2017551580 A JP 2017551580A JP 2017551580 A JP2017551580 A JP 2017551580A JP 2018509175 A5 JP2018509175 A5 JP 2018509175A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific tetravalent
- tetravalent antibody
- cancer
- pharmaceutical composition
- binding specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 9
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- -1 trastuzumab Chemical compound 0.000 claims 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004421 formestane Drugs 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068859A JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095348P | 2014-12-22 | 2014-12-22 | |
| US62/095,348 | 2014-12-22 | ||
| PCT/US2015/066951 WO2016106157A1 (en) | 2014-12-22 | 2015-12-19 | Bispecific tetravalent antibodies and methods of makiing and using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068859A Division JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509175A JP2018509175A (ja) | 2018-04-05 |
| JP2018509175A5 true JP2018509175A5 (enExample) | 2019-02-07 |
| JP6947639B2 JP6947639B2 (ja) | 2021-10-13 |
Family
ID=56151464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551580A Active JP6947639B2 (ja) | 2014-12-22 | 2015-12-19 | 二重特異性四価抗体並びにその製作及び使用方法 |
| JP2021068859A Active JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068859A Active JP7335290B2 (ja) | 2014-12-22 | 2021-04-15 | 二重特異性四価抗体並びにその製作及び使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10717783B2 (enExample) |
| EP (3) | EP4491195A3 (enExample) |
| JP (2) | JP6947639B2 (enExample) |
| KR (4) | KR102548827B1 (enExample) |
| CN (11) | CN113512120B (enExample) |
| AU (1) | AU2015369831B2 (enExample) |
| CA (1) | CA2969867C (enExample) |
| DK (1) | DK3237005T3 (enExample) |
| ES (2) | ES2995733T3 (enExample) |
| FI (1) | FI3237005T3 (enExample) |
| HR (1) | HRP20241502T1 (enExample) |
| HU (1) | HUE069256T2 (enExample) |
| IL (3) | IL305193A (enExample) |
| LT (1) | LT3237005T (enExample) |
| NZ (1) | NZ732628A (enExample) |
| PL (1) | PL3237005T3 (enExample) |
| PT (1) | PT3237005T (enExample) |
| RS (1) | RS66070B1 (enExample) |
| SG (1) | SG11201704741PA (enExample) |
| SI (1) | SI3237005T1 (enExample) |
| SM (1) | SMT202400477T1 (enExample) |
| WO (2) | WO2016106158A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| US12428483B2 (en) | 2014-12-22 | 2025-09-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| CN108948195B (zh) * | 2017-05-23 | 2022-05-31 | 胡毅 | 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途 |
| EP3645741A4 (en) * | 2017-06-25 | 2021-08-25 | Systimmune, Inc. | ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING |
| EP3703736A4 (en) * | 2017-11-02 | 2021-11-03 | Systimmune, Inc. | BISPECIFIC ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF |
| JP7316284B2 (ja) * | 2018-01-15 | 2023-07-27 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する抗体及びその多様体 |
| CN107974461A (zh) * | 2018-01-18 | 2018-05-01 | 东北农业大学 | 一种高效表达anti-hEGFR基因的真核表达载体构建方法 |
| CN108220244A (zh) * | 2018-01-18 | 2018-06-29 | 东北农业大学 | 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺 |
| EP3774914A2 (en) * | 2018-04-13 | 2021-02-17 | Affimed GmbH | Nk cell engaging antibody fusion constructs |
| WO2019222428A1 (en) * | 2018-05-16 | 2019-11-21 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| JP7193058B2 (ja) * | 2018-08-08 | 2022-12-20 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質 |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| CN113544144A (zh) * | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| AU2020214336B2 (en) * | 2019-01-30 | 2026-06-04 | The Wistar Institute Of Anatomy And Biology | DNA-encoded bispecific T-cell engagers targeting cancer antigens and methods of use in cancer theraputics |
| MX2022001027A (es) * | 2019-07-26 | 2022-04-18 | Abl Bio Inc | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. |
| CN114585651A (zh) | 2019-08-08 | 2022-06-03 | 再生元制药公司 | 新型抗原结合分子形式 |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| CN111548424A (zh) * | 2020-06-05 | 2020-08-18 | 上海科弈药业科技有限公司 | 一种靶向egfr与cd47的多功能融合蛋白及其应用 |
| CN116490523A (zh) * | 2020-09-21 | 2023-07-25 | 西雅图免疫公司 | 特异性增强的双特异性抗体（seba） |
| BR112023005152A2 (pt) * | 2020-09-21 | 2023-04-25 | Systimmune Inc | Anticorpo biespecífico com especificidade intensificada (seba) |
| CN117940459A (zh) * | 2021-08-25 | 2024-04-26 | 西雅图免疫公司 | 靶向egfr和her3的双特异性四价抗体 |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| WO2023044483A2 (en) * | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| AU2022357570A1 (en) * | 2021-10-03 | 2024-04-11 | Systimmune, Inc. | Methods of treating cancer and the pharmaceutical compositions thereof |
| JP7767613B2 (ja) * | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| WO2023241480A1 (zh) * | 2022-06-13 | 2023-12-21 | 三优生物医药(上海)有限公司 | 抗pd-l1、vegf和egfr三特异性抗体及其应用 |
| AU2023334288A1 (en) * | 2022-08-31 | 2025-03-20 | Systimmune, Inc. | Biepitopic tetravalent antibody targeting egfr |
| CN116063564A (zh) * | 2022-10-08 | 2023-05-05 | 盛禾(中国)生物制药有限公司 | 一种纯化融合蛋白的方法 |
| CN118829655A (zh) * | 2023-02-15 | 2024-10-22 | 浙江时迈药业有限公司 | Egfr和lag3双靶向的双特异性抗体及其用途 |
| CN121443647A (zh) * | 2023-07-07 | 2026-01-30 | 四川科伦博泰生物医药股份有限公司 | EGFR/c-MET双特异性结合蛋白及其用途 |
| EP4754149A1 (en) * | 2023-07-29 | 2026-06-10 | Shanghai Kaijin Biotechnology , Ltd | Modified type e multi-specific antibodies |
| KR20260117771A (ko) * | 2023-11-29 | 2026-07-29 | 시스트이뮨, 인코포레이티드 | Her2 및 her3을 표적하는 이중특이성 4가 항체 |
| WO2025140662A1 (en) * | 2023-12-29 | 2025-07-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-egfr/her3 antibodies and uses thereof |
| WO2025190404A1 (zh) * | 2024-03-14 | 2025-09-18 | 珠海普米斯生物科技有限公司 | 双特异性抗体、抗体药物偶联物及其应用 |
| WO2026103680A1 (zh) * | 2024-11-12 | 2026-05-21 | 江苏康宁杰瑞生物制药有限公司 | 双特异性抗体-多重有效载荷偶联物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2200753B (en) | 1986-12-23 | 1991-01-23 | Brookes & Gatehouse | Speed measurement device |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1472275B1 (en) * | 2002-02-05 | 2008-12-17 | Genentech, Inc. | Protein purification |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| JP2009540015A (ja) * | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗ｅｇｆｒ抗体の凍結乾燥製剤 |
| AU2007353412A1 (en) * | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR20150036824A (ko) * | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| AU2010229705A1 (en) * | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| CN102378768A (zh) * | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
| US9050375B2 (en) * | 2009-07-06 | 2015-06-09 | Hoffmann-La Roche, Inc. | Bi-specific digoxigenin binding antibodies |
| MX2012002651A (es) * | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| EP2496598B1 (en) * | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
| JP2014504850A (ja) * | 2010-09-30 | 2014-02-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| CN103384681B (zh) * | 2010-12-23 | 2018-05-18 | 霍夫曼-拉罗奇有限公司 | 结合剂 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MX336197B (es) * | 2011-04-19 | 2016-01-11 | Merrimack Pharmaceuticals Inc | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| US20140170148A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
| CA2832387A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| CN102250246A (zh) * | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| CN102250247B (zh) | 2011-06-15 | 2013-06-19 | 常州亚当生物技术有限公司 | 一种抗vegf/ang2双特异性抗体及其应用 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| US8961971B2 (en) * | 2011-12-22 | 2015-02-24 | Development Center For Biotechnology | Bispecific T-cell activator antibody |
| WO2013148315A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| IN2015DN01115A (enExample) * | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| CN104688740A (zh) * | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| CN104045714B (zh) * | 2013-03-14 | 2019-01-11 | 南京金斯瑞生物科技有限公司 | 曲妥珠单抗突变体IgG及其应用 |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| CN103509117B (zh) * | 2013-05-06 | 2016-03-09 | 江苏匡亚生物医药科技有限公司 | 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途 |
| US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
-
2015
- 2015-12-19 US US15/538,189 patent/US10717783B2/en active Active
- 2015-12-19 ES ES15874216T patent/ES2995733T3/es active Active
- 2015-12-19 KR KR1020177020104A patent/KR102548827B1/ko active Active
- 2015-12-19 JP JP2017551580A patent/JP6947639B2/ja active Active
- 2015-12-19 PT PT158742163T patent/PT3237005T/pt unknown
- 2015-12-19 IL IL305193A patent/IL305193A/en unknown
- 2015-12-19 CN CN202110470818.XA patent/CN113512120B/zh active Active
- 2015-12-19 CN CN201580036408.7A patent/CN106659779B/zh active Active
- 2015-12-19 CN CN201580073430.9A patent/CN107206074B/zh active Active
- 2015-12-19 SM SM20240477T patent/SMT202400477T1/it unknown
- 2015-12-19 FI FIEP15874216.3T patent/FI3237005T3/fi active
- 2015-12-19 AU AU2015369831A patent/AU2015369831B2/en active Active
- 2015-12-19 CN CN202110471245.2A patent/CN113512123B/zh active Active
- 2015-12-19 CN CN202110471392.XA patent/CN113105553B/zh active Active
- 2015-12-19 EP EP24200270.7A patent/EP4491195A3/en active Pending
- 2015-12-19 NZ NZ732628A patent/NZ732628A/en unknown
- 2015-12-19 CN CN202110471052.7A patent/CN113512121B/zh active Active
- 2015-12-19 EP EP15874217.1A patent/EP3237006B1/en active Active
- 2015-12-19 SI SI201532042T patent/SI3237005T1/sl unknown
- 2015-12-19 CN CN202110471082.8A patent/CN113512122B/zh active Active
- 2015-12-19 US US15/119,694 patent/US10919977B2/en active Active
- 2015-12-19 SG SG11201704741PA patent/SG11201704741PA/en unknown
- 2015-12-19 PL PL15874216.3T patent/PL3237005T3/pl unknown
- 2015-12-19 HR HRP20241502TT patent/HRP20241502T1/hr unknown
- 2015-12-19 CN CN202110471476.3A patent/CN113150165B/zh active Active
- 2015-12-19 EP EP15874216.3A patent/EP3237005B1/en active Active
- 2015-12-19 KR KR1020237021346A patent/KR102590385B1/ko active Active
- 2015-12-19 RS RS20241150A patent/RS66070B1/sr unknown
- 2015-12-19 CN CN202110470743.5A patent/CN113105551B/zh active Active
- 2015-12-19 WO PCT/US2015/066952 patent/WO2016106158A1/en not_active Ceased
- 2015-12-19 CN CN202311507433.1A patent/CN117467017A/zh active Pending
- 2015-12-19 KR KR1020237034930A patent/KR102823201B1/ko active Active
- 2015-12-19 CA CA2969867A patent/CA2969867C/en active Active
- 2015-12-19 KR KR1020257020085A patent/KR20250094744A/ko active Pending
- 2015-12-19 HU HUE15874216A patent/HUE069256T2/hu unknown
- 2015-12-19 IL IL286835A patent/IL286835B2/en unknown
- 2015-12-19 DK DK15874216.3T patent/DK3237005T3/da active
- 2015-12-19 LT LTEPPCT/US2015/066951T patent/LT3237005T/lt unknown
- 2015-12-19 ES ES15874217T patent/ES2962675T3/es active Active
- 2015-12-19 CN CN202110470781.0A patent/CN113105552B/zh active Active
- 2015-12-19 WO PCT/US2015/066951 patent/WO2016106157A1/en not_active Ceased
-
2017
- 2017-06-11 IL IL252811A patent/IL252811B/en unknown
-
2021
- 2021-04-15 JP JP2021068859A patent/JP7335290B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| US12384853B2 (en) | Anti-HER2/PD1 bispecific antibody | |
| JP2020531043A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2019524693A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2014527814A5 (enExample) | ||
| JP2013527762A5 (enExample) | ||
| RU2020120613A (ru) | Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения | |
| JP2014503189A5 (enExample) | ||
| JP2021501575A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2024520577A (ja) | 抗ｎｋｇ２ａ抗体及び組成物 | |
| WO2025016459A1 (zh) | 一种抗fgfr2/pd-1双特异性抗体 | |
| US12428483B2 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| CN104650228A (zh) | 一种全人源her2抗体、其编码基因及应用 | |
| HK40120554A (en) | Bispecific tetravalent antibodies and methods of makiing and using thereof | |
| RU2024107459A (ru) | Биспецифическое тетравалентное антитело против egfr и her3 | |
| CN104497140A (zh) | 一种全人源her2抗体、其编码基因及应用 | |
| RU2026103949A (ru) | Антитела против pd-1/ctla-4/vegf и их применение | |
| JP2023509973A5 (enExample) |